BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21831545)

  • 1. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
    Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
    Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
    Pal SK; Sartor O
    Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
    Pal SK; Sartor O
    Asian J Androl; 2011 Sep; 13(5):683-9. PubMed ID: 21602834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-resistant prostate cancer: systemic therapy in 2012.
    Maluf FC; Smaletz O; Herchenhorn D
    Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

  • 9. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
    Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
    J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
    J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Nabhan C
    N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
    [No Abstract]   [Full Text] [Related]  

  • 16. Current clinical trials in castrate-resistant prostate cancer.
    Petrylak DP
    Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.